$0.00
0.00%
Nasdaq, Jul 18, 03:30 pm CET
ISIN
US65344D1090
Symbol
NEXI
Sector
Industry

Neximmune Inc Stock price

$0.00
+0.00 0.00% 1M
-0.10 99.90% 6M
-0.12 99.91% YTD
-2.17 100.00% 1Y
-40.50 100.00% 3Y
-425.00 100.00% 5Y
-425.00 100.00% 10Y
-425.00 100.00% 20Y
Nasdaq, Closing price Fri, Jul 18 2025
+0.00 0.00%
ISIN
US65344D1090
Symbol
NEXI
Sector
Industry

Key metrics

Basic
Market capitalization
$0.0
Enterprise Value
$-2.4m
Net debt
positive
Cash
$2.4m
Shares outstanding
1.4m
Valuation (TTM | estimate)
P/E
0.0 | 0.0
P/S
- | -
EV/Sales
- | -
EV/FCF
0.1
P/B
0.0
Financial Health
Equity Ratio
40.8%
Return on Equity
-
ROCE
-1,800.0%
ROIC
-
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$0.0 | $0.0
EBITDA
$-19.5m | -
EBIT
$-20.2m | $-29.2m
Net Income
$-20.6m | $-210.0k
Free Cash Flow
$-17.6m
Growth (TTM | estimate)
Revenue
- | -
EBITDA
60.0% | -
EBIT
59.5% | -
Net Income
57.7% | -
Free Cash Flow
58.2%
Margin (TTM | estimate)
Gross
-
EBITDA
- | -
EBIT
-
Net
- | -
Free Cash Flow
-
More
EPS
$-14.9
FCF per Share
$-12.7
Short interest
1.3%
Employees
6
Rev per Employee
-
Show more

Is Neximmune Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,010 stocks worldwide.

Neximmune Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

7 Analysts have issued a Neximmune Inc forecast:

6x Buy
86%
1x Hold
14%

Analyst Opinions

7 Analysts have issued a Neximmune Inc forecast:

Buy
86%
Hold
14%

Financial data from Neximmune Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '24
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 10 10
25% 25%
-
- Research and Development Expense 9.67 9.67
73% 73%
-
-19 -19
60% 60%
-
- Depreciation and Amortization 0.69 0.69
34% 34%
-
EBIT (Operating Income) EBIT -20 -20
59% 59%
-
Net Profit -21 -21
58% 58%
-

In millions USD.

Don't miss a Thing! We will send you all news about Neximmune Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Company Profile

NexImmune, Inc. engages in the development of novel approach to immunotheraphy designed to create therapies with curative potential for patients with cancer and other life threatening immune-mediated diseases. Its product candidates are NEXI-001 in acute myeloid leukemia, or AML, and NEXI-002 in multiple myeloma, or MM. The company was founded by Kenneth C. Carter, Jonathan Schneck, and Mathias Oelke in June 7, 2011 and is headquartered in Gaithersburg, MD.

Head office United States
CEO Craig Jalbert
Employees 6
Founded 2011
Website www.neximmune.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today